Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
18.50
0.00 (0.00%)
At close: Oct 23, 2025
TEVJF Revenue
Teva Pharmaceutical Industries had revenue of $4.18B in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
16.63B
Revenue Growth
+2.07%
P/S Ratio
1.40
Revenue / Employee
449.41K
Employees
35,686
Market Cap
23.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Teva Pharmaceutical Industries News
- 9 days ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 9 days ago - Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe - GuruFocus
- 10 days ago - Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - GlobeNewsWire
- 13 days ago - Teva Vs. Viatris: Who Will Dominate In President Trump's America? - Seeking Alpha
- 14 days ago - AFI Development - Vedomosti (Ведомости)
- 17 days ago - TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Nasdaq
- 19 days ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 19 days ago - FDA Expands Use of Teva's (TEVA) Uzedy for Bipolar I Disorder - GuruFocus